Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables broadly unchanged from a year ago
Net receivables stood at CA$340.58K at the end of Q1 FY2026, down 1.8% from a year earlier and up 50.6% from the prior quarter. Over 3 fiscal years it compounded at -13.9% a year.
Context
- Net receivables amounted to 1.1% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -1.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
CAD · from the balance sheet
- Latest · FY2025
- 226.2K CAD
- Year-over-year change
- -37.4%
- 4-year CAGR
- +36.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 226.2K | -37.4% |
| FY2024 | 2024-12-31 | 361.62K | +29.2% |
| FY2023 | 2023-12-31 | 279.87K | -21.0% |
| FY2022 | 2022-12-31 | 354.24K | +438.9% |
| FY2021 | 2021-12-31 | 65.74K | — |
Net Receivables vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.8% is the highest of 7, against a peer median of -17.3%.
- Net receivables amounts to 1.1% of total assets for CRDL, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | ₪154.47M ILS | -14.4% | +46.1% | 22.4% | |
| Mar 2026 | $61.53M USD | -7.2% | +38.3% | 29.1% | |
| Mar 2026 | $5.8M USD | -20.2% | +27.7% | 9.6% | |
| Mar 2026 | €1.65M EUR | -2.4% | -0.1% | 3.4% | |
| Mar 2026 | CA$340.58K CAD | -1.8% | -13.9% | 1.1% | |
| Dec 2025 | $161K USD | -84.7% | -11.5% | 0.3% | |
| Mar 2026 | $105K USD | — | +32.8% | 0.1% | |
| Mar 2026 | $12K USD | -93.1% | — | 0.0% | |
IMAImageneBio Inc | Mar 2026 | $0 USD | — | — | 0.0% |
KLRSKalaris Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding CRDL) | — | -17.3% | +30.2% | 0.3% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83.9M | 43.83M | 34.93M | 30.58M | 21.42M |
| Short-term Investments | 0 | 45.65K | 0 | 0 | 0 |
| Net Receivables | 65.74K | 354.24K | 279.87K | 361.62K | 226.2K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 341.39K | 0 | 0 | 0 | 0 |
| Total Current Assets | 87.14M | 45.32M | 36.15M | 31.67M | 23.5M |
| Property, Plant & Equipment (Net) | 356.49K | 218.17K | 337.06K | 195.59K | 118.09K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 379.25K | 217.48K | 210.36K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 735.74K | 435.64K | 547.42K | 195.59K | 118.09K |
| Total Assets | 87.88M | 45.76M | 36.7M | 31.86M | 23.62M |
| Account Payables | 4.14M | 6.16M | 7.62M | 6.98M | 0 |
| Short-term Debt | 0 | 37.21K | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.66M | 1.04M | 238.18K | 0 | 5.62M |
| Total Current Liabilities | 11.57M | 7.23M | 8.3M | 7.01M | 5.66M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | (0) | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 72.87K | 16.54K | 158.53K | 125.52K | 87.18K |
| Total Liabilities | 11.64M | 7.25M | 8.45M | 7.14M | 5.74M |
| Common Stock | 142.92M | 108.84M | 148.52M | 179.34M | 201.87M |
| Retained Earnings | (83.52M) | (84.43M) | (142.58M) | (179.25M) | (213.07M) |
| Accumulated OCI | 4.18M | 2.6M | 3.52M | 0 | 0 |
| Other Stockholders Equity | 829 | 0 | (666) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 76.24M | 38.51M | 28.25M | 24.73M | 17.88M |
| Total Debt | 117.58K | 53.76K | 174.34K | 158.53K | 125.52K |
| Net Debt | (83.78M) | (43.77M) | (34.76M) | (30.42M) | (21.29M) |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.